Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1397038 | 0.86 | GAA (0.43) | GAAHSD17B10USP2JAK1ALDH1A1 | |
| SCHEMBL12984848 | 0.83 | HCAR1 (0.52) | GAAUSP2ALDH1A1KMT2AHPGD | |
| SCHEMBL1396944 | 0.79 | GABRG2 (0.46) | — | |
| SCHEMBL1870574 | 0.77 | DDB1 (0.50) | GAAHSD17B10USP2ALDH1A1KMT2A | |
| SCHEMBL1834469 | 0.76 | USP2 (0.63) | GAAHSD17B10USP2JAK1ALDH1A1 | |
| SCHEMBL1868756 | 0.75 | GAA (0.52) | GAAHSD17B10USP2ALDH1A1KMT2A | |
| SCHEMBL12075901 | 0.73 | FGFR1 (0.48) | GAAHSD17B10USP2ALDH1A1KMT2A | |
| SCHEMBL12075903 | 0.73 | FGFR1 (0.48) | GAAHSD17B10USP2ALDH1A1KMT2A | |
| SCHEMBL12985013 | 0.73 | HCAR1 (0.50) | GAAJAK1ALDH1A1KMT2AHPGD | |
| SCHEMBL2731216 | 0.73 | HCAR1 (0.50) | GAAJAK1ALDH1A1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288601-B1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| US-8530468-B2 | Bicyclylaryl-aryl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-09-10 | — | — | US | disclosed |
| EP-2288601-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2011-03-02 | — | — | EP | disclosed |
| US-20100331328-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-12-30 | — | — | US | disclosed |
| WO-2009103966-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331328-A1 | BICYCLYLARYL-ARYL-AMINE COMPOUNDS AND THEIR USE | CHEK1, CHEK2, BUB1B | GAA 1262/4885HSD17B10 2434/4885USP2 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.